DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

BNTX·BioNTech SE

$.
+. (+.%)
High
$96.08
Open
$94.19
Market Cap
23.30B
52W High
$124.00
Low
$92.25
P. Close
$92.25
P/E
-
52W Low
$79.52
Fwd P/E
-
Mean Target
$123.04
Technical Score (1D)
27
SELL
News Sentiment
47
MIXED
Bernstein initiated coverage on BioNTech with a "Market Perform" rating and a price target of $96, providing a new valuation benchmark. This analyst view follows recent news of BioNTech's Supervisory Board expansion with oncology and commercial expertise, a move aimed at bolstering its pipeline and addressing investor concerns amidst recent share price pressure. Shareholders approved all agenda items at the recent Annual General Meeting, including this board expansion, signaling broad support for management's strategic direction which emphasizes a growing focus on its late-stage oncology pipeline. In parallel, BioNTech is set to showcase significant clinical data from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting, including promising updates for pumitamig in lung cancer and gotistobart in ovarian cancer. The company also announced a new $1 billion ADS repurchase program, authorized through May 2027, reflecting a strong financial position and a strategy to enhance capital efficiency. Earlier, BioNTech implemented layoffs due to declining COVID-19 vaccine revenues, indicating an operational adjustment to market shifts. Traders should monitor the upcoming ASCO presentations for clinical validation of its oncology candidates and the execution of its multi-product strategy.
Earnings Summary
BioNTech SE is a German biotechnology firm established in 2008, specializing in the development and commercialization of immunotherapies for cancer and infectious diseases. Headquartered in Mainz, Germany, the company's core focus is on its pipeline of innovative drug candidates undergoing clinical trials across various phases, targeting a range of solid tumors and other cancers. The biotechnology sector is characterized by high R&D investment and significant regulatory hurdles, making pipeline progression and clinical trial success critical for valuation. In its most recent reported quarters, BioNTech experienced a significant shift in performance. For Q4 2024, the company reported an actual EPS of $1.08 against an estimate of $0.37, alongside actual revenue of $1.19 billion with no estimate provided. This contrasts with Q4 2025, where actual EPS was -$0.33 against an estimate of -$2.02, and actual revenue was $907.17 million against an estimate of $320.74 million. The trend shows a substantial deceleration in revenue and a move from a positive to a negative EPS in the subsequent quarter. Analyzing historical performance, BioNTech has demonstrated an inconsistent beat/miss pattern against analyst estimates. While Q4 2024 saw a significant EPS beat, the subsequent reported quarters, Q4 2025 and Q1 2026, have shown actual EPS figures that were considerably better than the negative estimates, indicating a potential trend of exceeding lowered expectations or improving operational performance relative to forecasts. However, revenue trends have shown volatility, with Q4 2025 revenue significantly exceeding estimates, followed by a sharp decline in Q1 2026 actual revenue to $118.17 million against an estimate of $248.53 million. Recent news highlights BioNTech's active advancement of its oncology pipeline, with presentations of clinical data for pumitamig and gotistobart at the 2026 ASCO Annual Meeting, signaling progress in late-stage development. The company has also expanded its Supervisory Board with new members to bolster clinical and oncology expertise, aiming to enhance governance and guide the advancement of its cancer therapies. While these developments suggest a strategic focus on strengthening its oncology pipeline and commercialization efforts, investors will be watching for continued progress in clinical trials and the translation of enhanced board expertise into improved financial performance and pipeline success in the coming quarters. Key watch points for the next reporting period will include the revenue trajectory following the recent decline and the continued demonstration of positive clinical trial outcomes that can support future growth.

EPS

EstBeatMiss
$-2.92$-1.79$-0.66$0.47$1.60Q4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-2.40 - -
Q1'26$-2.29$-1.95+15.0%
Q4'25$-2.02$-0.33+83.9%
Q4'24$0.37$1.08+188.9%

Revenue

EstBeatMiss
$-43M$306M$654M$1.0B$1.4BQ4'24Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$228M - -
Q1'26$249M$118M-52.5%
Q4'25$321M$907M+182.8%
Q4'24 - $1.2B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BNTX Stock Snapshot

BNTX is currently trading at $94.21, giving BioNTech SE a market cap of 23.30B. Today's range spans $92.25–$96.08, with shares opening at $94.19 and moving up $1.96 (2.1%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 47/100.

Over the past year BNTX has traded between $79.52 and $124.00 - the current price is +18.5% off the 52-week low and -24.0% from the high. 28 analysts cover the stock with a Buy consensus and a mean 12-month target of $123.04 (range $75.82–$156.93), implying upside of +30.6%.

BioNTech SE (BNTX) is at $94.21 (in the lower half of its 52-week range in $79.52–$124.00), carrying a SELL signal (27/100) and neutral sentiment (47/100). The 23.30B market cap in Healthcare means this name is well-covered by analysts who can accelerate the downside through rating cuts and target reductions - a feedback loop that smaller stocks with less coverage don't face to the same degree.

When a large-cap Healthcare name with 23.30B in capitalization prints a SELL signal (27/100) alongside neutral news sentiment (47/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $94.21 (in the lower half of its 52-week range in the $79.52–$124.00 range), the structural support levels are where that sponsorship question gets answered.